神经内分泌肿瘤药物临床试验进展

doi:10.19401/j.cnki.1007-3639.2022.09.001

摘要/Abstract

摘要：

神经内分泌肿瘤（neuroendocrine neoplasm,NEN）是一类起源于神经内分泌细胞及肽能神经元的高度异质性的少见肿瘤。根据细胞分化的程度,NEN可分为分化好的神经内分泌瘤（neuroendocrine tumor,NET）和分化差的神经内分泌癌（neuroendocrine carcinoma,NEC）。药物治疗是进展期NEN患者首选的全身治疗方式。本文总结了近年来在NEN领域的重要药物临床试验进展,为临床治疗提供参考。

关键词: 神经内分泌肿瘤, 药物, 临床试验

Abstract:

Neuroendocrine neoplasm (NEN) is a group of heterogeneous malignancies arising from neuroendocrine cells and peptidergic neurons. According to its cell differentiation, NEN can be divided into two distinct groups as well-differentiated neuroendocrine tumor (NET) and poorly-differentiated neuroendocrine carcinoma (NEC). For advanced NEN, medication is the preferred treatment. In this article, we reviewed current clinical trials in medical treatment for NEN and aimed to provide treatment reference in clinical practice.

Key words: Neuroendocrine neoplasms, Medicine, Clinical trial

中图分类号:

R730.5

梁贇, 吉顺荣, 虞先濬, 陈洁. 神经内分泌肿瘤药物临床试验进展[J]. 中国癌症杂志, 2022, 32(9): 757-764.

LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie. Updates on medical treatment for neuroendocrine neoplasm[J]. China Oncology, 2022, 32(9): 757-764.

参考文献 50

[1]	DASARI A, SHEN C, HALPERIN D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335-1342. doi: 10.1001/jamaoncol.2017.0589 pmid: 28448665
[2]	WHO Classification of Tumours Editorial Board. WHO classification of tumours of digestive system[M]. Lyon: IARC Press, 2019.
[3]	WHO Classification of Tumours Editorial Board. Thoracic tumours[M]. 5th ed. International Agency for Research on Cancer, Lyon, France, 2021.
[4]	CAPLIN M E, PAVEL M, ĆWIKŁA J B, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371(3): 224-233. doi: 10.1056/NEJMoa1316158
[5]	CAPLIN M E, PAVEL M, PHAN A T, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study[J]. Endocrine, 2021, 71(2): 502-513. doi: 10.1007/s12020-020-02475-2 pmid: 33052555
[6]	JIMENEZ-FONSECA P, CARMONA-BAYONAS A, LAMARCA A, et al. External validity of somatostatin analogs trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study[J]. Neuroendocrinology, 2022, 112(1): 88-100. doi: 10.1159/000514808
[7]	BAUDIN E, HORSCH D, SINGH S, et al. Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase Ⅲ SPINET study[J]. Ann Oncol, 2021, 32: S906. doi: 10.1016/j.annonc.2021.08.178
[8]	PAVEL M, ĆWIKŁA J B, LOMBARD-BOHAS C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results[J]. Eur J Cancer, 2021, 157: 403-414. doi: 10.1016/j.ejca.2021.06.056 pmid: 34597974
[9]	LEPAGE C, DAHAN L, BOUARIOUA N, et al. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours[J]. Dig Liver Dis, 2017, 49(5): 568-571. doi: 10.1016/j.dld.2017.02.004
[10]	LEPAGE C, PHELIP J M, LIÈVRE A, et al. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): an international double-blind, placebo-controlled randomized phase Ⅱ trial[J]. Ann Oncol, 2020, 31: S774.
[11]	LIU Y M, LIU H K, CHEN W C, et al. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J]. Cancer Med, 2022, 11(13): 2588-2600. doi: 10.1002/cam4.4628
[12]	FEROLLA P, BRIZZI M P, MEYER T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial[J]. Lancet Oncol, 2017, 18(12): 1652-1664. doi: S1470-2045(17)30681-2 pmid: 29074099
[13]	PAVEL M E, HAINSWORTH J D, BAUDIN E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2011, 378(9808): 2005-2012. doi: S0140-6736(11)61742-X pmid: 22119496
[14]	RAYMOND E, DAHAN L, RAOUL J L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 501-513. doi: 10.1056/NEJMoa1003825
[15]	XU J M, SHEN L, BAI C M, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(11): 1489-1499. doi: 10.1016/S1470-2045(20)30493-9 pmid: 32966810
[16]	LI J, XU J, ZHOU Z, et al. Safety profile and adverse events of special interest for surufatinib in chinese patients with advanced extra-pancreatic neuroendocrine tumors: analysis of the phase 3 SANET-ep trial[J]. Lung, 2020, 37: 4585-4598.
[17]	CAPDEVILA J, FAZIO N, LOPEZ LOPEZ C, et al. Final results of the TALENT trial (GETNE1509): a prospective multicohort phase Ⅱ study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs)[J]. J Clin Oncol, 2019, 37(15_suppl): 4106.
[18]	CAPDEVILA J, JIMENEZ-VALERIO G, MARTINEZ A, et al. Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: results from the international phase Ⅱ TALENT trial (GETNE 1509)[J]. J Clin Oncol, 2021, 39(15_suppl): 4113. doi: 10.1200/JCO.2021.39.15_suppl.4113
[19]	STROSBERG J R, CIVES M, HWANG J, et al. A phase Ⅱ study of axitinib in advanced neuroendocrine tumors[J]. Endocr Relat Cancer, 2016, 23(5): 411-418. doi: 10.1530/ERC-16-0008
[20]	LEVY S, VERBEEK W H M, ESKENS F A L M, et al. First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial[J]. Ther Adv Med Oncol, 2022, 14: 17588359221077088.
[21]	中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022(6): 545-580.
	Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. China Oncol, 2022(6): 545-580.
[22]	GIROT P, BAUDIN E, SENELLART H, et al. Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French group of endocrine tumors[J]. Neuroendocrinology, 2022, 112(6): 537-546. doi: 10.1159/000518650
[23]	BUTT B P, STOKMO H L, LADEKARL M, et al. Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas[J]. Ann Oncol, 2021, 32: S915.
[24]	ACOMBE C, PERRIER M, HENTIC O, et al. FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors[J]. Ann Oncol, 2021, 32(suppl_5): S621-S625.
[25]	MEHNERT J M, BERGSLAND E, O’NEIL B H, et al. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study[J]. Cancer, 2020, 126(13): 3021-3030. doi: 10.1002/cncr.32883 pmid: 32320048
[26]	STROSBERG J, MIZUNO N, DOI T, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study[J]. Clin Cancer Res, 2020, 26(9): 2124-2130. doi: 10.1158/1078-0432.CCR-19-3014
[27]	LU M, ZHANG P P, ZHANG Y Q, et al. Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase ib trial[J]. Clin Cancer Res, 2020, 26(10): 2337-2345. doi: 10.1158/1078-0432.CCR-19-4000 pmid: 32086343
[28]	PATEL S P, OTHUS M, CHAE Y K, et al. A phase Ⅱ basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors[J]. Clin Cancer Res, 2020, 26(10): 2290-2296. doi: 10.1158/1078-0432.CCR-19-3356
[29]	Thoracique IFdC, Digestive FFdC, Group G-MOC (2019) Nivolumab +/- ipilimumab in patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs)[EB/OL]. (2020-10-09)[2022-08-25]. https://clinicaltrials.gov/show/NCT03591731.
[30]	CAPDEVILA J, TEULE A, LÓPEZ C, et al. A multi-cohort phase Ⅱ study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601)[J]. Ann Oncol, 2020, 31: S770-S771.
[31]	HORN L, MANSFIELD A S, SZCZĘSNA A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229. doi: 10.1056/NEJMoa1809064
[32]	PAZ-ARES L, DVORKIN M, CHEN Y B, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939. doi: 10.1016/S0140-6736(19)32222-6
[33]	RIESCO-MARTINEZ M C, CAPDEVILA J, ALONSO V, et al. Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: preliminary results from the phase Ⅱ NICE-NEC trial (GETNE T1913)[J]. Ann Oncol, 2021, 32: S908-S909. doi: 10.1016/j.annonc.2021.08.180
[34]	HALPERIN D M, LIU S Y, DASARI A, et al. Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial[J]. JAMA Oncol, 2022, 8(6): 904-909. doi: 10.1001/jamaoncol.2022.0212 pmid: 35389428
[35]	CAO Y S, LU M, SUN Y, et al. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial[J]. J Cancer Res Clin Oncol, 2022. Online ahead of print.
[36]	WHALEN K A, WHITE B H, QUINN J M, et al. Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer[J]. Mol Cancer Ther, 2019, 18(11): 1926-1936. doi: 10.1158/1535-7163.MCT-19-0022 pmid: 31649014
[37]	SAUNDERS L R, BANKOVICH A J, ANDERSON W C, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo[J]. Sci Transl Med, 2015, 7(302): 302ra136.
[38]	DENG S M, YAN X C, LIANG L, et al. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice[J]. Biochem Biophys Res Commun, 2017, 483(1): 488-494. doi: 10.1016/j.bbrc.2016.12.117
[39]	HERMANS B C M, DERKS J L, THUNNISSEN E, et al. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile[J]. Lung Cancer, 2019, 138: 102-108. doi: S0169-5002(19)30680-4 pmid: 31678831
[40]	MATSUO K, TANIGUCHI K, HAMAMOTO H, et al. Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy[J]. Cancer Sci, 2019, 110(10): 3122-3131. doi: 10.1111/cas.14157
[41]	RUDIN C M, PIETANZA M C, BAUER T M, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study[J]. Lancet Oncol, 2017, 18(1): 42-51. doi: S1470-2045(16)30565-4 pmid: 27932068
[42]	MORGENSZTERN D, BESSE B, GREILLIER L, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase Ⅱ TRINITY study[J]. Clin Cancer Res, 2019, 25(23): 6958-6966. doi: 10.1158/1078-0432.CCR-19-1133
[43]	MORGENSZTERN D, JOHNSON M, RUDIN C M, et al. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study[J]. Lung Cancer, 2020, 145: 126-131. doi: S0169-5002(20)30387-1 pmid: 32438272
[44]	MIYAGAWA-HAYASHINO A, OKADA S, TAKEDA-MIYATA N, et al. TTF-1 and c-MYC-defined phenotypes of large cell neuroendocrine carcinoma and delta-like protein 3 expression for treatment selection[J]. Appl Immunohistochem Mol Morphol, 2021, 29(4): 313-320. doi: 10.1097/PAI.0000000000000875
[45]	THOMAS A, TAKAHASHI N, RAJAPAKSE V N, et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress[J]. Cancer Cell, 2021, 39(4): 566-579.e7. doi: 10.1016/j.ccell.2021.02.014 pmid: 33848478
[46]	JONASCH E, DONSKOV F, ILIOPOULOS O, et al. Belzutifan for renal cell carcinoma in von hippel-lindau disease[J]. N Engl J Med, 2021, 385(22): 2036-2046. doi: 10.1056/NEJMoa2103425
[47]	KLEMPNER S J, GERSHENHORN B, TRAN P, et al. BRAF V600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy[J]. Cancer Discov, 2016, 6(6): 594-600. doi: 10.1158/2159-8290.CD-15-1192 pmid: 27048246
[48]	IDREES K, PADMANABHAN C, LIU E, et al. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma[J]. J Surg Oncol, 2018, 117(2): 284-289. doi: 10.1002/jso.24834
[49]	CAPDEVILA J, ARQUÉS O, HERNÁNDEZ MORA J R, et al. Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAF V600E blockade in colon neuroendocrine carcinomas[J]. Clin Cancer Res, 2020, 26(4): 902-909. doi: 10.1158/1078-0432.CCR-19-1266
[50]	BURKART J, OWEN D, SHAH M H, et al. Targeting BRAF mutations in high-grade neuroendocrine carcinoma of the colon[J]. J Natl Compr Canc Netw, 2018, 16(9): 1035-1040. doi: 10.6004/jnccn.2018.7043